Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development
October 15, 2015 2:12 PM EDTNEW YORK--(BUSINESS WIRE)-- Today, Bristol-Myers Squibb Company (NYSE: BMY) announced that Paul Biondi has been appointed senior vice president, head of Business Development and will report to... More
Ovid Therapeutics Announces Appointment of Dr. Anna Kazanchyan to Senior Vice President, Business Development
October 15, 2015 8:00 AM EDTNEW YORK--(BUSINESS WIRE)-- Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today the appointment of Anna Kazanchyan, M.D., to the newly created position of Senior Vice President, Business Development. Dr. Kazanchyan will head corporate and business development activities at Ovid, where she will plan, seek, and execute transactions and establish and manage external alliances with industry and academia. She will report to Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. Dr. Kazanchyan previously served as Senior Vice President, Product Development at Ovid, having... More
Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
October 15, 2015 4:05 AM EDTSOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will host a conference call and live audio webcast today, October 15 at 8:30 a.m. (ET)/5:30 a.m. (PT) to discuss the new worldwide license and... More
Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
October 15, 2015 4:05 AM EDTSOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will host a conference call and live audio webcast today, October 15 at 8:30 a.m. (ET)/5:30 a.m. (PT) to discuss the new worldwide license and... More
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM EDTStrategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients
Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.
Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology... More
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM EDTStrategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients
Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.
Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology... More
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM EDTStrategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients
Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.
Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology... More
Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM EDTStrategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients
Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.
Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology candidates
NEW YORK & SOUTH SAN FRANCISCO, Calif--(BUSINESS... More
Market’s Only Cancer Immunotherapy ETF Launches
October 14, 2015 9:05 AM EDTExchange Traded Concepts Partners with Loncar Investments, ISE ETF Ventures, and Amplify Development on the Loncar Cancer Immunotherapy ETF (NASDAQ: CNCR)
Cancer immunotherapy companies are beneficially disrupting cancer treatment by deploying bodys own immune system to fight disease ETF seeks to track index developed by biotechnology investor Brad Loncar ETF offers diversified exposure to both pharmaceutical companies and clinical-stage biotechnology firms having immunotherapy focus
OKLAHOMA... More
Bristol-Myers Squibb's Ready. Raise. Rise.™ Recognizes 23 Cancer Advocacy Groups in Immuno-Oncology Research Awareness Campaign
October 13, 2015 6:59 AM EDTMore than 50,000 virtual flags raised to honor loved ones and support cancer advocacy groups Charitable donations were awarded to Chris4Life Colon Cancer Foundation, Cancer Support Community and CancerCare for having the most flags raised on their behalf, recognizing their commitment to increasing awareness of Immuno-Oncology research
NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb today announced that more than 50,000 virtual flags have been raised by Americans across the country as part of the Ready. Raise. Rise. campaign, a program dedicated to raising awareness and educating the public about an exciting... More
